Pfizer Taps Sage Bionetworks to Build Cancer Models for Drug Discovery, Development

Sage president Stephen Friend said that Sage "offers a way to accelerate [Pfizer's] efforts to use integrative genomics to inform their drug development decisions."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.